Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424808 | 1.00 | ABL1 (0.64) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL31250286 | 0.95 | ABL1 (0.57) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL31250315 | 0.95 | ABL1 (0.57) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL31250303 | 0.91 | GSK3B (0.57) | ABL1JAK2TYK2LRRK2 | |
| SCHEMBL24394296 | 0.89 | GSK3B (0.53) | ABL1JAK2TYK2MAP4K1 | |
| SCHEMBL24394291 | 0.89 | ABL1 (0.51) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL24394275 | 0.89 | ABL1 (0.51) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL29567522 | 0.89 | ABL1 (0.51) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL24394277 | 0.86 | ABL1 (0.48) | ABL1JAK2TYK2MAP4K1LRRK2 | |
| SCHEMBL31250323 | 0.86 | ABL1 (0.49) | ABL1JAK2TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516039-B2 | N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4236950-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406844-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | ABL1 215/4885JAK2 342/4885TYK2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.